Evaluation of IL‐6 levels and +3954 polymorphism of IL‐1β in burning mouth syndrome: A systematic review and meta‐analysis

This study evaluated IL‐6 salivary levels as well as the +3954 polymorphism of IL‐1β in patients with burning mouth syndrome and healthy individuals, through case‐control studies. This systematic review and meta‐analysis followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses...

Full description

Saved in:
Bibliographic Details
Published inJournal of oral pathology & medicine Vol. 49; no. 10; pp. 961 - 968
Main Authors Campello, Camilla Porto, Pellizzer, Eduardo Piza, Vasconcelos, Belmiro Cavalcanti do Egito, Moraes, Sandra Lúcia Dantas, Lemos, Cleidiel Aparecido Araújo, Muniz, Maria Tereza Cartaxo
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study evaluated IL‐6 salivary levels as well as the +3954 polymorphism of IL‐1β in patients with burning mouth syndrome and healthy individuals, through case‐control studies. This systematic review and meta‐analysis followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. We conducted this research in PubMed/MEDLINE, Cochrane Library and Web of Science databases. The risk of bias was measured based in the Newcastle‐Ottawa Scale. Researches with a group of patients with burning mouth syndrome and a control group in which the presence of the +3954 polymorphism of IL‐1β and/ or IL‐6 salivary levels through non‐stimulated saliva were evaluated to detect if this interleukin concentrations are increased in patients and if the polymorphism is a risk factor for this syndrome. We identified seven studies with total of 440 participants, 229 patients with burning mouth syndrome and 211 healthy controls, ages 24‐84 years old. The female gender was predominant. Patients in the majority of studies did not present increased levels of IL‐6 and the +3954 polymorphism of IL‐1β is not a risk factor for this syndrome. A few studies researched biomarkers in this pathology and more investigations are required not only to identify salivary levels and the polymorphism evaluated, but also other interleukins and polymorphisms in order to clarify the etiopathogenesis of this syndrome as well as for propose new diagnostic methods and treatments.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0904-2512
1600-0714
DOI:10.1111/jop.13018